Selective galactose culture condition reveals distinct metabolic signatures in pyruvate dehydrogenase and complex I deficient human skin fibroblasts.
Cell Line
Electron Transport Complex I
/ metabolism
Energy Metabolism
/ physiology
Female
Fibroblasts
/ metabolism
Galactose
/ metabolism
Glucose
/ metabolism
Humans
Magnetic Resonance Spectroscopy
/ methods
Male
Mitochondria
/ metabolism
Primary Cell Culture
Pyruvate Dehydrogenase Complex Deficiency Disease
/ metabolism
Pyruvates
/ metabolism
Skin
/ metabolism
Complex I
Galactose
Mitochondrial dysfunction
NMR
Pyruvate dehydrogenase
Journal
Metabolomics : Official journal of the Metabolomic Society
ISSN: 1573-3890
Titre abrégé: Metabolomics
Pays: United States
ID NLM: 101274889
Informations de publication
Date de publication:
28 02 2019
28 02 2019
Historique:
received:
08
10
2018
accepted:
21
02
2019
entrez:
5
3
2019
pubmed:
5
3
2019
medline:
9
4
2020
Statut:
epublish
Résumé
A decline in mitochondrial function represents a key factor of a large number of inborn errors of metabolism, which lead to an extremely heterogeneous group of disorders. To gain insight into the biochemical consequences of mitochondrial dysfunction, we performed a metabolic profiling study in human skin fibroblasts using galactose stress medium, which forces cells to rely on mitochondrial metabolism. Fibroblasts from controls, complex I and pyruvate dehydrogenase (PDH) deficient patients were grown under glucose or galactose culture condition. We investigated extracellular flux using Seahorse XF24 cell analyzer and assessed metabolome fingerprints using NMR spectroscopy. Incubation of fibroblasts in galactose leads to an increase in oxygen consumption and decrease in extracellular acidification rate, confirming adaptation to a more aerobic metabolism. NMR allowed rapid profiling of 41 intracellular metabolites and revealed clear separation of mitochondrial defects from controls under galactose using partial least squares discriminant analysis. We found changes in classical markers of mitochondrial metabolic dysfunction, as well as unexpected markers of amino acid and choline metabolism. PDH deficient cell lines showed distinct upregulation of glutaminolytic metabolism and accumulation of branched-chain amino acids, while complex I deficient cell lines were characterized by increased levels in choline metabolites under galactose. Our results show the relevance of selective culture methods in discriminating normal from metabolic deficient cells. The study indicates that untargeted fingerprinting NMR profiles provide physiological insight on metabolic adaptations and can be used to distinguish cellular metabolic adaptations in PDH and complex I deficient fibroblasts.
Identifiants
pubmed: 30830487
doi: 10.1007/s11306-019-1497-2
pii: 10.1007/s11306-019-1497-2
doi:
Substances chimiques
Pyruvates
0
Electron Transport Complex I
EC 7.1.1.2
Glucose
IY9XDZ35W2
Galactose
X2RN3Q8DNE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Commentaires et corrections
Type : ErratumIn
Références
EMBO J. 2013 Jan 9;32(1):9-29
pubmed: 23149385
J Neurol Sci. 1996 Feb;135(2):176-80
pubmed: 8867076
Biochim Biophys Acta. 1998 May 6;1364(2):271-86
pubmed: 9593934
J Inherit Metab Dis. 1996;19(4):452-62
pubmed: 8884569
Chimia (Aarau). 2017 Mar 29;71(3):124-129
pubmed: 28351458
J Med Genet. 1994 Nov;31(11):875-9
pubmed: 7853374
Annu Rev Nutr. 1984;4:409-54
pubmed: 6380539
Cancer Res. 2004 Feb 1;64(3):985-93
pubmed: 14871829
Science. 2013 Dec 20;342(6165):1453-4
pubmed: 24357304
Magn Reson Med. 1999 Oct;42(4):643-54
pubmed: 10502752
Sci Rep. 2017 Aug 17;7(1):8652
pubmed: 28819133
Mol Genet Metab. 2008 May;94(1):16-37
pubmed: 18243024
Methods Enzymol. 2000;324:465-76
pubmed: 10989453
Nat Protoc. 2010 Jun;5(6):1019-32
pubmed: 20539278
Nat Rev Endocrinol. 2014 Dec;10(12):723-36
pubmed: 25287287
Cell Metab. 2017 Feb 7;25(2):374-385
pubmed: 28178567
Anal Chem. 2006 Jul 1;78(13):4281-90
pubmed: 16808434
Neurology. 1999 Apr 12;52(6):1255-64
pubmed: 10214753
Cell Metab. 2006 Jan;3(1):9-13
pubmed: 16399500
Hum Mutat. 2000;15(2):123-34
pubmed: 10649489
Neurotherapeutics. 2013 Apr;10(2):273-85
pubmed: 23208728
Int J Biochem Cell Biol. 1996 Jul;28(7):787-93
pubmed: 8925409
J Neurosci Res. 2005 Jan 1-15;79(1-2):65-73
pubmed: 15578726
J Inherit Metab Dis. 2003;26(2-3):199-207
pubmed: 12889661
Toxicol Sci. 2007 Jun;97(2):539-47
pubmed: 17361016
Metabolomics. 2008 Dec 1;4(4):347-356
pubmed: 19774105
PLoS One. 2011;6(12):e28536
pubmed: 22194845
Biochem Med Metab Biol. 1992 Oct;48(2):122-6
pubmed: 1329873
Oncotarget. 2016 Aug 16;7(33):53837-53852
pubmed: 27462778
Chem Commun (Camb). 2012 Jan 21;48(6):811-3
pubmed: 22143456
Metabolomics. 2018;14(5):55
pubmed: 29937703
N Engl J Med. 2012 Mar 22;366(12):1132-41
pubmed: 22435372
PLoS One. 2015 May 29;10(5):e0128478
pubmed: 26024484
Xenobiotica. 1999 Nov;29(11):1181-9
pubmed: 10598751
Mol Cell. 2014 Nov 6;56(3):414-24
pubmed: 25458842
Nucleic Acids Res. 2013 Jan;41(Database issue):D801-7
pubmed: 23161693
Analyst. 2017 Jan 26;142(3):465-471
pubmed: 28074201
Curr Top Med Chem. 2011;11(1):2-26
pubmed: 20809888
Biochim Biophys Acta. 2004 Jul 23;1658(1-2):80-8
pubmed: 15282178